Back to Search
JEFFERY N GLASPY MD
MD
Emergency Medicine Physician
NPI: 1619925237IndividualAccepts Medicare
Specialties, Licenses & Credentials
Emergency Medicine PhysicianPrimary
Emergency Medicine
Code: 207P00000X
41367(WI)
Education
MEDICAL COLLEGE OF WISCONSIN
Class of 1998
Research & Publications (20)
Intratumoral immune cell infiltrates, FoxP3, and indoleamine 2,3-dioxygenase in patients with melanoma undergoing CTLA4 blockade.
PMID 19118070·Clin Cancer Res·2009
8-other
Pooled analysis of individual patient-level data from all randomized, double-blind, placebo-controlled trials of darbepoetin alfa in the treatment of patients with chemotherapy-induced anemia.
PMID 19380447·J Clin Oncol·2009
1-meta
Interferon alfa in the postsurgical management of high-risk melanoma: is it worth it?
PMID 19433677·J Clin Oncol·2009
8-other
Initiation of epoetin-alpha therapy at a starting dose of 120,000 units once every 3 weeks in patients with cancer receiving chemotherapy: an open-label, multicenter study with randomized and nonrandomized treatment arms.
PMID 19170225·Cancer·2009
4-observational
Budget impact analysis of darbepoetin alfa every 3 weeks versus epoetin alfa every week for the treatment of chemotherapy-induced anaemia from a US payer's perspective.
PMID 19450080·J Med Econ·2008
4-observational
High-molecular weight iron dextran: a wolf in sheep's clothing?
PMID 18369084·J Am Soc Nephrol·2008
8-other
Detailed analysis of immunologic effects of the cytotoxic T lymphocyte-associated antigen 4-blocking monoclonal antibody tremelimumab in peripheral blood of patients with melanoma.
PMID 18452610·J Transl Med·2008
3-trial
Darbepoetin alpha for the treatment of anemia in patients with active cancer not receiving chemotherapy or radiotherapy: results of a phase III, multicenter, randomized, double-blind, placebo-controlled study.
PMID 18227526·J Clin Oncol·2008
3-trial
Adenovirus MART-1-engineered autologous dendritic cell vaccine for metastatic melanoma.
PMID 18317358·J Immunother·2008
3-trial
Phase II study of two dose schedules of C.E.R.A. (Continuous Erythropoietin Receptor Activator) in anemic patients with advanced non-small cell lung cancer (NSCLC) receiving chemotherapy.
PMID 17341293·Trials·2007
8-other
Surveillance of the eye and vision in clinical trials of CP-675,206 for metastatic melanoma.
PMID 17434437·Am J Ophthalmol·2007
3-trial
A randomized, open-label, multicenter trial of immediate versus delayed intervention with darbepoetin alfa for chemotherapy-induced anemia.
PMID 17962619·Oncologist·2007
4-observational
Immunosensitization of tumor cells to dendritic cell-activated immune responses with the proteasome inhibitor bortezomib (PS-341, Velcade).
PMID 16585569·J Immunol·2006
7-preclinical
A phase I/II trial testing immunization of hepatocellular carcinoma patients with dendritic cells pulsed with four alpha-fetoprotein peptides.
PMID 16675576·Clin Cancer Res·2006
3-trial
Optimizing the dose and schedule of darbepoetin alfa in patients with chemotherapy-induced anemia.
PMID 16925109·Oncology (Williston Park)·2006
6-review
Definition of an immunologic response using the major histocompatibility complex tetramer and enzyme-linked immunospot assays.
PMID 16397031·Clin Cancer Res·2006
4-observational
Data courtesy of the U.S. National Library of Medicine (NLM). Ltrl is not affiliated with or endorsed by NLM.
Contact & Hours
- Address
- 1284 N SUMMIT AVE
OCONOMOWOC, WI 53066 - Phone
- (262) 569-3080
Quick Facts
- NPI
- 1619925237
- Entity Type
- Individual
- Gender
- Male
- Medicare
- Accepted
- Specialties
- 1
- Locations
- 1
- Years in Practice
- 28
- Publications
- 20
Are you this provider?
Claim Your Profile